Last reviewed · How we verify
Basal insulins
At a glance
| Generic name | Basal insulins |
|---|---|
| Also known as | Glargine, Detemir, Degludec |
| Sponsor | Laniado Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Surgical or Medical Treatment (PHASE4)
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (PHASE2)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (PHASE1)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- Optimization of Basal Insulin During Ramadan Fasting in Type 2 Diabetic Patients: Comparison Between DAR Recommendations and the Carbohydrate Fasting Test & Metabolic and Inflammatory Consequences (EARLY_PHASE1)
- The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants. (NA)
- A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |